Presents a comprehensive framework for approaching target validation in drug discovery. This work begins with a description of enabling technologies, including aptamers, RNA interference, and proteomics. It, then, looks at biologic drug development with discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin.
Bio de l'auteur
Sommaire / contenu